Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Myoinositol

Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile

DRUG

Chromium

chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation

DRUG

l-arginine

new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO

DRUG

Letrozole 2.5mg

selective aromatase inhibitor

Trial Locations (2)

62511

Beni-suef university Hospital, Banī Suwayf

Beni-suef university, Banī Suwayf

All Listed Sponsors
lead

Beni-Suef University

OTHER